

EMOSIS SAS announces the appointment of Nicolas Rufin as Head of marketing and sales

Strasbourg, France March 2017

Emosis SAS, an in vitro diagnostics company specialized in cell-based hemostasis gladly announces today that Nicolas Rufin has joined the company to support the team efforts prior to the launch of its first kit.

Nicolas brings to Emosis his experience and strong knowledge of the business and scientific environment related to haemostasis, both in laboratory and Point of Care area. He spent almost 25 years working as a sales and marketing professional, handling international distributors and covering global Marketing functions, for key players of the Diagnostics hemostasis industry, such as Roche Diagnostics and Stago. Most recently, Nicolas worked in International Sales and Marketing for DSM Pentapharm, where he developed an international distributors network beside managing some direct key accounts from the hemostasis industry.

Joining Emosis as the Head of Marketing and Sales prior to the launch of a first-in-class IVD kit for Heparin Induced Thrombocytopenia (HIT), Nicolas will select and manage an international distributor network. He will also contribute to the company Marketing and commercial strategy, of course with its associated sales development plan.

“Emosis is all about enlightening medical decisions through precise diagnostics. Being part of such an adventure is really stimulating, especially when we are getting closer to the launch of the first product” said Nicolas. “The portfolio we are currently developing will support Emosis being at the forefront of a relatively untapped concept called cellular hemostasis. We reckon it represents the future of hemostasis, as it entails all components involved in the process of what happens in vivo in patients” he added.

About Emosis SAS

Emosis SAS, a French MedTech company founded early 2015 by Prof. Aaron Tomer and Dr. Frederic Allemand, to address largely unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders – hemostasis and thrombosis in medical parlance. Emosis uniquely applies, in a user-friendly way, the power of flow cytometry technology within the emerging paradigm of cell-based hemostasis - or cell-based coagulation, to enlighten medical decision of the physicians managing those patients.

Visit www.emosis-diagnostics.com and follow us on LinkedIn.

Contact

Frédéric Allemand, CEO, frederic.allemand@emosis-diagnostics.com

Nicolas Rufin, Head of marketing and sales, nicolas.rufin@emosis-diagnostics.com

www.emosis-diagnostics.com
